Part 1 - Myeloma: The New Playbook

The Bleeding Edge of Discovery: What does the next decade of myeloma care look like? In this first installment, Dr. Tania Small brings together three of the world’s foremost experts to explore the breakthroughs redefining hope in multiple myeloma. From minimal residual disease (MRD) as a new regulatory endpoint to the research of immune-based therapies and the transformative potential these may hold, the panel dissects how science is accelerating toward the possibility of a functional cure. They also tackle some of the field’s toughest questions: how to sequence therapy in an era of quads, bispecifics, and antibody-drug conjugates, and how to close the survival gap for underrepresented populations by translating biology into equitable access.